Ontology highlight
ABSTRACT:
SUBMITTER: Gonzalez-Alonso P
PROVIDER: S-EPMC7281325 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
González-Alonso Paula P Zazo Sandra S Martín-Aparicio Ester E Luque Melani M Chamizo Cristina C Sanz-Álvarez Marta M Minguez Pablo P Gómez-López Gonzalo G Cristóbal Ion I Caramés Cristina C García-Foncillas Jesús J Eroles Pilar P Lluch Ana A Arpí Oriol O Rovira Ana A Albanell Joan J Piersma Sander R SR Jimenez Connie R CR Madoz-Gúrpide Juan J Rojo Federico F
Cancers 20200429 5
Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired resistance to trastuzumab. We established an acquired trastuzumab-resistant model in vitro from BT-474, a trastuzumab-sensitive, HER2-amplified breast-cancer cell line. A multi-omic strategy was implemented to obtain gene, proteome, and phosphoproteome si ...[more]